Barclays Has Lowered Expectations for InMode (NASDAQ:INMD) Stock Price

InMode (NASDAQ:INMD) had its target price decreased by stock analysts at Barclays from $27.00 to $26.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the healthcare company’s stock. Barclays‘s price objective would suggest a potential upside of 63.52% from the company’s current price.

A number of other equities analysts have also recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research note on Thursday, October 31st. BTIG Research began coverage on shares of InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.40.

InMode Stock Down 0.7 %

Shares of NASDAQ INMD opened at $15.90 on Thursday. The stock’s fifty day simple moving average is $18.06 and its 200 day simple moving average is $17.30. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of 8.59 and a beta of 2.12. InMode has a 52-week low of $14.87 and a 52-week high of $26.80.

Institutional Investors Weigh In On InMode

A number of institutional investors have recently bought and sold shares of the business. Doma Perpetual Capital Management LLC boosted its holdings in shares of InMode by 210.7% during the second quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock worth $36,685,000 after purchasing an additional 1,363,841 shares during the period. Federated Hermes Inc. lifted its position in InMode by 191.9% in the 2nd quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock worth $20,520,000 after buying an additional 739,629 shares in the last quarter. Lombard Odier Asset Management Europe Ltd acquired a new stake in shares of InMode during the 2nd quarter valued at $4,104,000. Systematic Financial Management LP grew its holdings in shares of InMode by 34.5% during the 2nd quarter. Systematic Financial Management LP now owns 866,619 shares of the healthcare company’s stock valued at $15,807,000 after acquiring an additional 222,532 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of InMode by 11.6% in the second quarter. Renaissance Technologies LLC now owns 2,068,396 shares of the healthcare company’s stock worth $37,728,000 after acquiring an additional 214,200 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.